Search

Your search keyword '"Douglas, Alexander D."' showing total 248 results
Start Over Author "Douglas, Alexander D."
248 results on '"Douglas, Alexander D."'

1. Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex

Author

Williams, Barnabas G., King, Lloyd D. W., Pulido, David, Quinkert, Doris, Lias, Amelia M., Silk, Sarah E., Ragotte, Robert J., Davies, Hannah, Barrett, Jordan R., McHugh, Kirsty, Rigby, Cassandra A., Alanine, Daniel G. W., Barfod, Lea, Shea, Michael W., Cowley, Li An, Dabbs, Rebecca A., Pattinson, David J., Douglas, Alexander D., Lyth, Oliver R., Illingworth, Joseph J., Jin, Jing, Carnrot, Cecilia, Kotraiah, Vinayaka, Christen, Jayne M., Noe, Amy R., MacGill, Randall S., King, C. Richter, Birkett, Ashley J., Soisson, Lorraine A., Skinner, Katherine, Miura, Kazutoyo, Long, Carole A., Higgins, Matthew K., and Draper, Simon J.

Published
2024
Full Text
View/download PDF

4. Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial

Author

Jenkin, Daniel, Ritchie, Adam J, Aboagye, Jeremy, Fedosyuk, Sofiya, Thorley, Luke, Provstgaad-Morys, Samuel, Sanders, Helen, Bellamy, Duncan, Makinson, Rebecca, Xiang, Zhi Quan, Bolam, Emma, Tarrant, Richard, Ramos Lopez, Fernando, Platt, Abigail, Poulton, Ian, Green, Catherine, Ertl, Hildegund C J, Ewer, Katie J, and Douglas, Alexander D

Published
2022
Full Text
View/download PDF

6. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Author

Adlou, Syed, Aley, Robert, Ali, Aabidah, Anslow, Rachel, Baker, Megan, Baker, Phillip, Barrett, Jordan R., Bates, Louise, Beadon, Kirsten, Beckley, Rebecca, Bell, Jonathan, Bellamy, Duncan, Beveridge, Amy, Bissett, Cameron, Blackwell, Luke, Bletchly, Heather, Boyd, Amy, Bridges-Webb, Alice, Brown, Charlie, Byard, Nicholas, Camara, Susana, Cifuentes Gutierrez, Liliana, Collins, Andrea M., Cooper, Rachel, Crocker, Wendy E.M., Darton, Thomas C., Davies, Hannah, Davies, Judith, Demissie, Tesfaye, Di Maso, Claudio, Dinesh, Tanya, Donnellan, Francesca R., Douglas, Alexander D., Drake-Brockman, Rachael, Duncan, Christopher J.A., Elias, Sean C., Emary, Katherine R.W., Ghulam Farooq, Mutjaba, Faust, Saul N., Felle, Sally, Ferreira, Daniela, Ferreira Da Silva, Carla, Finn, Adam, Ford, Karen J., Francis, Emma, Furze, Julie, Fuskova, Michelle, Galiza, Eva, Gibertoni Cruz, Ana, Godfrey, Leila, Goodman, Anna L., Green, Catherine, Green, Christopher A., Greenwood, Nicola, Harrison, Daisy, Hart, Thomas C., Hawkins, Sophia, Heath, Paul T., Hill, Helen, Hillson, Kushalinii, Horsington, Bryn, Hou, Mimi M., Howe, Elizabeth, Howell, Nicola, Joe, Carina, Jones, Elizabeth, Kasanyinga, Mwila, Keen, Jade, Kelly, Sarah, Kerr, David, Khan, Liaquat, Khozoee, Baktash, Kinch, Jasmin, Kinch, Patrick, Koleva, Stanislava, Kwok, Jonathan, Larkworthy, Colin W., Lawrie, Alison M., Lazarus, Rajeka, Lees, Emily A., Li, Grace, Libri, Vincenzo, Lillie, Patrick J., Linder, Aline, Long, Fei, Lopez Ramon, Raquel, Mabbett, Reece, Makinson, Rebecca, Marinou, Spyridoula, Marlow, Emma, Marshall, Julia L., Mazur, Olga, McEwan, Joanne, McGregor, Alastair C., Mokaya, Jolynne, Morey, Ella, Morshead, Gertraud, Morter, Richard, Muller, Jilly, Mweu, Philomena, Noristani, Rabiullah, Owino, Nelly, Polo Peralta Alvarez, Marco, Platt, Abigail, Pollock, Katrina M., Poulton, Ian, Provstgaard-Morys, Samuel, Pulido-Gomez, David, Rajan, Matthew, Ramos Lopez, Fernando, Ritchie, Adam, Roberts, Hannah, Rollier, Christine, Rudiansyah, Indra, Sanders, Katherine, Saunders, Jack E., Seddiqi, Samiullah, Sharpe, Hannah R., Shaw, Robert, Silva-Reyes, Laura, Singh, Nisha, Smith, David J., Smith, Catherine C., Smith, Andrew, Spencer, Alexandra J., Stuart, Arabella S.V., Sutherland, Rebecca, Szigeti, Anna, Tang, Karly, Thomas, Merin, Thomas, Tonia M., Thompson, Amber, Thomson, Emma C., Török, Estée M., Toshner, Mark, Tran, Nguyen, Trivett, Rose, Turnbull, Iain, Turner, Cheryl, Turner, David P.J., Ulaszewska, Marta, Vichos, Iason, Walker, Laura, Watson, Marion E., Whelan, Conor, White, Rachel, Williams, Sarah J., Williams, Christopher J.A., Wright, Daniel, Yao, Andy, Flaxman, Amy, Marchevsky, Natalie G, Jenkin, Daniel, Aboagye, Jeremy, Aley, Parvinder K, Angus, Brian, Belij-Rammerstorfer, Sandra, Bibi, Sagida, Bittaye, Mustapha, Cappuccini, Federica, Cicconi, Paola, Clutterbuck, Elizabeth A, Davies, Sophie, Dejnirattisai, Wanwisa, Dold, Christina, Ewer, Katie J, Folegatti, Pedro M, Fowler, Jamie, Hill, Adrian V S, Kerridge, Simon, Minassian, Angela M, Mongkolsapaya, Juthathip, Mujadidi, Yama F, Plested, Emma, Ramasamy, Maheshi N, Robinson, Hannah, Sanders, Helen, Sheehan, Emma, Smith, Holly, Snape, Matthew D, Song, Rinn, Woods, Danielle, Screaton, Gavin, Gilbert, Sarah C, Voysey, Merryn, Pollard, Andrew J, and Lambe, Teresa

Published
2021
Full Text
View/download PDF

7. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Author

Watson, Marion E.E., Song, Rinn, Cicconi, Paola, Minassian, Angela M., Bibi, Sagida, Kerridge, Simon, Singh, Nisha, Green, Catherine M., Douglas, Alexander D., Lawrie, Alison M., Clutterbuck, Elizabeth A., Frater, John, Ewer, Katie J, Ogbe, Ane, Pace, Mathew, Adele, Sandra, Adland, Emily, Alagaratnam, Jasmini, Aley, Parvinder K, Ali, Mohammad, Ansari, M Azim, Bara, Anna, Bittaye, Mustapha, Broadhead, Samantha, Brown, Anthony, Brown, Helen, Cappuccini, Federica, Cooney, Enya, Dejnirattisai, Wanwisa, Dold, Christina, Fairhead, Cassandra, Fok, Henry, Folegatti, Pedro M, Fowler, Jamie, Gibbs, Charlotte, Goodman, Anna L, Jenkin, Daniel, Jones, Mathew, Makinson, Rebecca, Marchevsky, Natalie G, Mujadidi, Yama F, Nguyen, Hanna, Parolini, Lucia, Petersen, Claire, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Rhead, Sarah, Robinson, Hannah, Robinson, Nicola, Rongkard, Patpong, Ryan, Fiona, Serrano, Sonia, Tipoe, Timothy, Voysey, Merryn, Waters, Anele, Zacharopoulou, Panagiota, Barnes, Eleanor, Dunachie, Susanna, Goulder, Philip, Klenerman, Paul, Screaton, Gavin R, Winston, Alan, Hill, Adrian V S, Gilbert, Sarah C, Pollard, Andrew J, Fidler, Sarah, Fox, Julie, and Lambe, Teresa

Published
2021
Full Text
View/download PDF

8. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

Author

Minassian, Angela M., Silk, Sarah E., Barrett, Jordan R., Nielsen, Carolyn M., Miura, Kazutoyo, Diouf, Ababacar, Loos, Carolin, Fallon, Jonathan K., Michell, Ashlin R., White, Michael T., Edwards, Nick J., Poulton, Ian D., Mitton, Celia H., Payne, Ruth O., Marks, Michael, Maxwell-Scott, Hector, Querol-Rubiera, Antonio, Bisnauthsing, Karen, Batra, Rahul, Ogrina, Tatiana, Brendish, Nathan J., Themistocleous, Yrene, Rawlinson, Thomas A., Ellis, Katherine J., Quinkert, Doris, Baker, Megan, Lopez Ramon, Raquel, Ramos Lopez, Fernando, Barfod, Lea, Folegatti, Pedro M., Silman, Daniel, Datoo, Mehreen, Taylor, Iona J., Jin, Jing, Pulido, David, Douglas, Alexander D., de Jongh, Willem A., Smith, Robert, Berrie, Eleanor, Noe, Amy R., Diggs, Carter L., Soisson, Lorraine A., Ashfield, Rebecca, Faust, Saul N., Goodman, Anna L., Lawrie, Alison M., Nugent, Fay L., Alter, Galit, Long, Carole A., and Draper, Simon J.

Published
2021
Full Text
View/download PDF

9. Developing novel blood-stage malaria vaccines

Author

Douglas, Alexander D., Draper, Simon J., Hill, Adrian V. S., and Sattentau, Quentin

Subjects
616.9, Parasitology, Infectious diseases, Immunology, Disease prevention, Medical sciences, Malaria, Vaccinology, Vaccine, Blood-Stage, PfRH5, Viral vector, Antibody
Abstract

Natural exposure to Plasmodium falciparum’s asexual blood-stage results in protection against severe disease, but no vaccine using the widely-studied blood-stage antigens apical membrane antigen 1 (AMA1) or merozoite surface protein 1 (MSP1) has proven convincingly protective in clinical trials. Challenges include antigenic polymorphism, the apparent requirement for exceptionally high antibody concentrations for protection, and clinical-grade production of conformationally-accurate recombinant protein antigens followed by formulation with a human-compatible adjuvant. This thesis describes the generation of viral-vectored vaccines targeting ten less-studied blood-stage antigens, focusing upon antigens implicated in erythrocyte invasion. These vaccines were immunogenic in mice and rabbits. The rabbit antibodies raised were functionally active in the in vitro assay of parasite growth inhibitory activity (GIA). GIA with antibodies against one antigen, RH5, exceeded that achieved with antibodies against the ‘gold standard’ AMA1 or MSP1 antigens. This antigen’s amino acid sequence is relatively conserved between parasite strains. Importantly, and unlike anti-AMA1 and MSP1 antibodies, the GIA effects transcend genetically diverse strains. It was hypothesised that blockade of the interaction of RH5 with its receptor basigin was likely to be a mechanism of action of anti-RH5 antibodies. Vaccine-induced polyclonal anti-RH5 serum was found to be capable of blocking this interaction, as well as merozoite attachment to erythrocytes. A panel of RH5-specific monoclonal antibodies were raised: those which block the RH5-receptor interaction were capable of neutralising parasites. Minimal linear epitopes recognised by these antibodies were mapped, and are likely to be within or close to RH5’s receptor binding site. These data support prompt clinical testing of RH5-based vaccines, and shed light upon the mechanism of action of anti-RH5 antibodies. However substantial challenges remain in establishing whether this antigen, selected on the basis of the in vitro assay of GIA, will be capable of achieving in vivo protection against P. falciparum. Further work presented in this thesis addresses the use of quantitative PCR data to assess blood-stage vaccine efficacy in experimental human challenge with P. falciparum, and the use of surface plasmon resonance to establish more detailed characterisation of vaccine-induced antibody responses. Finally, the results of P. falciparum challenge of RH5-vaccinated Aotus nancymaae non-human primates are presented.

Published
2015

12. Accelerated and intensified manufacturing of an adenovirus‐vectored vaccine to enable rapid outbreak response.

Author

Joe, Carina C. D., Segireddy, Rameswara R., Oliveira, Cathy, Berg, Adam, Li, Yuanyuan, Doultsinos, Dimitrios, Scholze, Steffi, Ahmad, Asma, Nestola, Piergiuseppe, Niemann, Julia, and Douglas, Alexander D.

Abstract

The Coalition for Epidemic Preparedness Innovations' "100‐day moonshot" aspires to launch a new vaccine within 100 days of pathogen identification, followed by large‐scale vaccine availability within the "second hundred days." Here, we describe work to optimize adenoviral vector manufacturing for rapid response, by minimizing time to clinical trial and first large‐scale supply, and maximizing output from the available manufacturing footprint. We describe a rapid virus seed expansion workflow that allows vaccine release to clinical trials within 60 days of antigen sequence identification, followed by vaccine release from globally distributed sites within a further 40 days. We also describe a perfusion‐based upstream production process, designed to maximize output while retaining simplicity and suitability for existing manufacturing facilities. This improves upstream volumetric productivity of ChAdOx1 nCoV‐19 by approximately fourfold and remains compatible with the existing downstream process, yielding drug substance sufficient for 10,000 doses from each liter of bioreactor capacity. This accelerated manufacturing process, along with other advantages such as thermal stability, supports the ongoing value of adenovirus‐vectored vaccines as a rapidly adaptable and deployable platform for emergency response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Accelerated and intensified manufacturing of an adenovirus‐vectored vaccine to enable rapid outbreak response

Author

Joe, Carina C. D., primary, Segireddy, Rameswara R., additional, Oliveira, Cathy, additional, Berg, Adam, additional, Li, Yuanyuan, additional, Doultsinos, Dimitrios, additional, Scholze, Steffi, additional, Ahmad, Asma, additional, Nestola, Piergiuseppe, additional, Niemann, Julia, additional, and Douglas, Alexander D., additional

Published
2023
Full Text
View/download PDF

17. Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal ‘C-tag’

Author

Jin, Jing, Hjerrild, Kathryn A., Silk, Sarah E., Brown, Rebecca E., Labbé, Geneviève M., Marshall, Jennifer M., Wright, Katherine E., Bezemer, Sandra, Clemmensen, Stine B., Biswas, Sumi, Li, Yuanyuan, El-Turabi, Aadil, Douglas, Alexander D., Hermans, Pim, Detmers, Frank J., de Jongh, Willem A., Higgins, Matthew K., Ashfield, Rebecca, and Draper, Simon J.

Published
2017
Full Text
View/download PDF

19. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01

Author

Payne, Ruth O., Milne, Kathryn H., Elias, Sean C., Edwards, Nick J., Douglas, Alexander D., Brown, Rebecca E., Silk, Sarah E., Biswas, Sumi, Miura, Kazutoyo, Roberts, Rachel, Rampling, Thomas W., Venkatraman, Navin, Hodgson, Susanne H., Labbé, Geneviève M., Halstead, Fenella D., Poulton, Ian D., Nugent, Fay L., de Graaf, Hans, Sukhtankar, Priya, Williams, Nicola C., Ockenhouse, Christian F., Kathcart, April K., Qabar, Aziz N., Waters, Norman C., Soisson, Lorraine A., Birkett, Ashley J., Cooke, Graham S., Faust, Saul N., Woods, Colleen, Ivinson, Karen, McCarthy, James S., Diggs, Carter L., Vekemans, Johan, Long, Carole A., Hill, Adrian V. S., Lawrie, Alison M., Dutta, Sheetij, and Draper, Simon J.

Published
2016

20. A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates

Author

Douglas, Alexander D., Baldeviano, G. Christian, Jin, Jing, Miura, Kazutoyo, Diouf, Ababacar, Zenonos, Zenon A., Ventocilla, Julio A., Silk, Sarah E., Marshall, Jennifer M., Alanine, Daniel G. W., Wang, Chuan, Edwards, Nick J., Leiva, Karina P., Gomez-Puerta, Luis A., Lucas, Carmen M., Wright, Gavin J., Long, Carole A., Royal, Joseph M., and Draper, Simon J.

Published
2019
Full Text
View/download PDF

21. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

Author

Madhavan, Meera, primary, Ritchie, Adam J., additional, Aboagye, Jeremy, additional, Jenkin, Daniel, additional, Provstgaad-Morys, Samuel, additional, Tarbet, Iona, additional, Woods, Danielle, additional, Davies, Sophie, additional, Baker, Megan, additional, Platt, Abigail, additional, Flaxman, Amy, additional, Smith, Holly, additional, Belij-Rammerstorfer, Sandra, additional, Wilkins, Deidre, additional, Kelly, Elizabeth J., additional, Villafana, Tonya, additional, Green, Justin A., additional, Poulton, Ian, additional, Lambe, Teresa, additional, Hill, Adrian V.S., additional, Ewer, Katie J., additional, and Douglas, Alexander D., additional

Published
2022
Full Text
View/download PDF

22. A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies novel host-pathogen interactions

Author

Segireddy, Rameswara R, primary, Belda, Hugo, additional, Yang, Annie S. P., additional, Dundas, Kirsten, additional, Knoeckel, Julia, additional, Galaway, Francis, additional, Wood, Laura, additional, Quinkert, Doris, additional, Knuepfer, Ellen, additional, Treeck, Moritz, additional, Wright, Gavin J, additional, and Douglas, Alexander D, additional

Published
2022
Full Text
View/download PDF

23. Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals

Author

Hodgson, Susanne H., Ewer, Katie J., Bliss, Carly M., Edwards, Nick J., Rampling, Thomas, Anagnostou, Nicholas A., de Barra, Eoghan, Havelock, Tom, Bowyer, Georgina, Poulton, Ian D., de Cassan, Simone, Longley, Rhea, Illingworth, Joseph J., Douglas, Alexander D., Mange, Pooja B., Collins, Katharine A., Roberts, Rachel, Gerry, Stephen, Berrie, Eleanor, Moyle, Sarah, Colloca, Stefano, Cortese, Riccardo, Sinden, Robert E., Gilbert, Sarah C., Bejon, Philip, Lawrie, Alison M., Nicosia, Alfredo, Faust, Saul N., and Hill, Adrian V. S.

Published
2015

24. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Author

Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Yin, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth, Collins, Andrea M, Cutland, Clare, Darton, Thomas, Dheda, Keertan, Douglas, Alexander D, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie, Marshall, Richard P, Mendes, Ana Verena Almeida, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Nana, Anusha, Payadachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, Mili Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew, and Group, Oxford COVID Vaccine Trial

Published
2022
Full Text
View/download PDF

25. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Author

Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian John, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth, Collins, Andrea M, Cox, Tony, Darton, Thomas, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie, Flaxman, Amy, Faust, Saul N, Ferreira, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew, Consortium, COVID-19 Genomics UK COG-UK, and Group, Oxford COVID Vaccine Trial

Published
2022
Full Text
View/download PDF

27. Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration.

Author

Cheng Zhang, Adam Berg, Joe, Carina C. D., Dalby, Paul A., and Douglas, Alexander D.

Abstract

Distribution of vaccines which require refrigerated or frozen storage can be challenging and expensive. The adenovirus vector platform has been widely used for COVID-19 vaccines while several further candidate vaccines using the platform are in clinical development. In current liquid formulations, adenoviruses require distribution at 2–8 °C. The development of formulations suitable for ambient temperature distribution would be advantageous. Previous peer-reviewed reports of adenovirus lyophilization are relatively limited. Here, we report the development of a formulation and process for lyophilization of simian adenovirus-vectored vaccines based on the ChAdOx1 platform. We describe the iterative selection of excipients using a design of experiments approach, and iterative cycle improvement to achieve both preservation of potency and satisfactory cake appearance. The resulting method achieved in-process infectivity titre loss of around 50%. After drying, there was negligible further loss over a month at 30 °C. Around 30% of the predrying infectivity remained after a month at 45 °C. This performance is likely to be suitable for ‘last leg’ distribution at ambient temperature. This work may also facilitate the development of other product presentations using dried simian adenovirusvectored vaccines. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

Author

Jin, Jing, Tarrant, Richard D., Bolam, Emma J., Angell-Manning, Philip, Soegaard, Max, Pattinson, David J., Dulal, Pawan, Silk, Sarah E., Marshall, Jennifer M., Dabbs, Rebecca A., Nugent, Fay L., Barrett, Jordan R., Hjerrild, Kathryn A., Poulsen, Lars, Jørgensen, Thomas, Brenner, Tanja, Baleanu, Ioana N., Parracho, Helena M., Tahiri-Alaoui, Abdessamad, Whale, Gary, Moyle, Sarah, Payne, Ruth O., Minassian, Angela M., Higgins, Matthew K., Detmers, Frank J., Lawrie, Alison M., Douglas, Alexander D., Smith, Robert, de Jongh, Willem A., Berrie, Eleanor, Ashfield, Rebecca, and Draper, Simon J.

Published
2018
Full Text
View/download PDF

29. Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection

Author

Douglas, Alexander D., Edwards, Nick J., Duncan, Christopher J. A., Thompson, Fiona M., Sheehy, Susanne H., O'Hara, Geraldine A., Anagnostou, Nicholas, Walther, Michael, Webster, Daniel P., Dunachie, Susanna J., Porter, David W., Andrews, Laura, Gilbert, Sarah C., Draper, Simon J., Hill, Adrian V. S., and Bejon, Philip

Published
2013
Full Text
View/download PDF

32. Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs

Author

Joe, Carina C. D., primary, Jiang, Jinlin, additional, Linke, Thomas, additional, Li, Yuanyuan, additional, Fedosyuk, Sofiya, additional, Gupta, Gaurav, additional, Berg, Adam, additional, Segireddy, Rameswara R., additional, Mainwaring, David, additional, Joshi, Amar, additional, Cashen, Paul, additional, Rees, Byron, additional, Chopra, Nitin, additional, Nestola, Piergiuseppe, additional, Humphreys, Jonathan, additional, Davies, Sarah, additional, Smith, Nick, additional, Bruce, Scott, additional, Verbart, Dennis, additional, Bormans, Daan, additional, Knevelman, Carol, additional, Woodyer, Mark, additional, Davies, Lee, additional, Cooper, Lisa, additional, Kapanidou, Maria, additional, Bleckwenn, Nicole, additional, Pappas, Daniel, additional, Lambe, Teresa, additional, Smith, Daniel C., additional, Green, Catherine M., additional, Venkat, Raghavan, additional, Ritchie, Adam J., additional, Gilbert, Sarah C., additional, Turner, Richard, additional, and Douglas, Alexander D., additional

Published
2021
Full Text
View/download PDF

34. T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire

Author

Swanson, Phillip A., Padilla, Marcelino, Hoyland, Wesley, McGlinchey, Kelly, Fields, Paul A., Bibi, Sagida, Faust, Saul N., McDermott, Adrian B., Lambe, Teresa, Pollard, Andrew J., Durham, Nicholas M., Kelly, Elizabeth J., Adlou, Syed, Aley, Parvinder K., Angus, Brian, Anslow, Rachel, Baker, Philip, Bansal, Himanshu, Beveridge, Amy, Bridges-Webb, Alice, Ching, Steven, Cicconi, Paola, Clutterbuck, Elizabeth A., Collins, Andrea M., Darton, Thomas C., Demissie, Tesfaye, Dinesh, Tanya, Douglas, Alexander D., Duncan, Christopher J. A., Ewer, Katie J., Felle, Sally, Finn, Adam, Folegatti, Pedro M., Fuskova, Michelle, Gilbert, Sarah C., Goodman, Anna, Green, Christopher A., Harbolick, Elizabeth, Hart, Thomas C., Hayes, Susana, Hill, Adrian V. S., Jenkin, Daniel, Jepson, Brett M., Kasanyinga, Mwila, Kerridge, Simon, Libri, Vincenzo, Lillie, Patrick J., McGregor, Alastair C., Minassian, Angela M., Mujadidi, Yama F., Pilataxi, Fernanda, Plested, Emma, Provstgaard-Morys, Samuel, Ramasamy, Maheshi, Robinson, Hannah, Sanders, Katherine, Smith, Andrew, Snape, Matthew D., Song, Rinn, Sutherland, Rebecca K., Thomson, Emma C., Toshner, Mark, Turner, David P. J., Voysey, Merryn, and Williams, Christopher J.

Subjects
COVID-19 Vaccines, SARS-CoV-2, Immunogenicity, T cell, Vaccination, T-cell receptor, Receptors, Antigen, T-Cell, COVID-19, Biology, Peripheral blood mononuclear cell, Article, T cell mediated immunity, medicine.anatomical_structure, ChAdOx1 nCoV-19, Spike Glycoprotein, Coronavirus, Immunology, medicine, Humans, Receptor, CD8
Abstract

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (COVID-19) in clinical trials and real-world studies. We characterized CD4+ and CD8+ T-cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells (PBMCs) from 280 unique vaccine recipients aged 18–85 years who enrolled in the phase 2/3 COV002 trial. Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222. CD4+ Th2 responses following AZD1222 vaccination were not detected. Furthermore, AZD1222-specific Th1 and CD8+ T cells both displayed a high degree of polyfunctionality in all adult age groups. T-cell receptor (TCR) β sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses. Overall, AZD1222 vaccination induced a robust, polyfunctional Th1-dominated T-cell response, with broad CD4+ and CD8+ T-cell coverage across the SARS-CoV-2 spike protein.One Sentence SummaryPolyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222

Published
2021

35. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7), an exploratory analysis of a randomised controlled trial

Author

Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Cox, Tony, Darton, Thomas C, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie J, Flaxman, Amy L, Faust, Saul N, Ferreir, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie G, Minassian, Angela M, McGregor, Alastair C, Mujadidi, Yama F, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew J, Consortium, The COVID-19 Genomics UK, Project, The AMPHEUS, Group, The Oxford COVID-19 Vaccine Trial, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository

Abstract

A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the United Kingdom from November 2020. Here we report efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19, against this variant., COVID-19 Genomics UK is supported by funding from the Medical Research Council, part of UK Research and Innovation, the NIHR, and Genome Research, operating as the Wellcome Sanger Institute.

Published
2021
Full Text
View/download PDF

36. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Author

Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Cox, Tony, Darton, Thomas C, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie J, Flaxman, Amy L, Faust, Saul N, Ferreira, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie G, Minassian, Angela M, McGregor, Alastair C, Mujadidi, Yama F, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew J, COVID-19 Genomics UK Consortium, AMPHEUS Project, Oxford COVID-19 Vaccine Trial Group, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository

Subjects
Adult, Male, COVID-19 Vaccines, Adolescent, SARS-CoV-2, COVID-19, Middle Aged, Viral Load, Antibodies, Neutralizing, United Kingdom, Young Adult, COVID-19 Nucleic Acid Testing, ChAdOx1 nCoV-19, Humans, Female, Single-Blind Method, Nucleic Acid Amplification Techniques, Pandemics
Abstract

BACKGROUND: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. METHODS: Volunteers (aged ≥18 years) who were enrolled in phase 2/3 vaccine efficacy studies in the UK, and who were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 or a meningococcal conjugate control (MenACWY) vaccine, provided upper airway swabs on a weekly basis and also if they developed symptoms of COVID-19 disease (a cough, a fever of 37·8°C or higher, shortness of breath, anosmia, or ageusia). Swabs were tested by nucleic acid amplification test (NAAT) for SARS-CoV-2 and positive samples were sequenced through the COVID-19 Genomics UK consortium. Neutralising antibody responses were measured using a live-virus microneutralisation assay against the B.1.1.7 lineage and a canonical non-B.1.1.7 lineage (Victoria). The efficacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to vaccine received. Vaccine efficacy was calculated as 1 - relative risk (ChAdOx1 nCoV-19 vs MenACWY groups) derived from a robust Poisson regression model. This study is continuing and is registered with ClinicalTrials.gov, NCT04400838, and ISRCTN, 15281137. FINDINGS: Participants in efficacy cohorts were recruited between May 31 and Nov 13, 2020, and received booster doses between Aug 3 and Dec 30, 2020. Of 8534 participants in the primary efficacy cohort, 6636 (78%) were aged 18-55 years and 5065 (59%) were female. Between Oct 1, 2020, and Jan 14, 2021, 520 participants developed SARS-CoV-2 infection. 1466 NAAT positive nose and throat swabs were collected from these participants during the trial. Of these, 401 swabs from 311 participants were successfully sequenced. Laboratory virus neutralisation activity by vaccine-induced antibodies was lower against the B.1.1.7 variant than against the Victoria lineage (geometric mean ratio 8·9, 95% CI 7·2-11·0). Clinical vaccine efficacy against symptomatic NAAT positive infection was 70·4% (95% CI 43·6-84·5) for B.1.1.7 and 81·5% (67·9-89·4) for non-B.1.1.7 lineages. INTERPRETATION: ChAdOx1 nCoV-19 showed reduced neutralisation activity against the B.1.1.7 variant compared with a non-B.1.1.7 variant in vitro, but the vaccine showed efficacy against the B.1.1.7 variant of SARS-CoV-2. FUNDING: UK Research and Innovation, National Institute for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca.

Published
2021

37. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Author

Flaxman, Amy, primary, Marchevsky, Natalie G, additional, Jenkin, Daniel, additional, Aboagye, Jeremy, additional, Aley, Parvinder K, additional, Angus, Brian, additional, Belij-Rammerstorfer, Sandra, additional, Bibi, Sagida, additional, Bittaye, Mustapha, additional, Cappuccini, Federica, additional, Cicconi, Paola, additional, Clutterbuck, Elizabeth A, additional, Davies, Sophie, additional, Dejnirattisai, Wanwisa, additional, Dold, Christina, additional, Ewer, Katie J, additional, Folegatti, Pedro M, additional, Fowler, Jamie, additional, Hill, Adrian V S, additional, Kerridge, Simon, additional, Minassian, Angela M, additional, Mongkolsapaya, Juthathip, additional, Mujadidi, Yama F, additional, Plested, Emma, additional, Ramasamy, Maheshi N, additional, Robinson, Hannah, additional, Sanders, Helen, additional, Sheehan, Emma, additional, Smith, Holly, additional, Snape, Matthew D, additional, Song, Rinn, additional, Woods, Danielle, additional, Screaton, Gavin, additional, Gilbert, Sarah C, additional, Voysey, Merryn, additional, Pollard, Andrew J, additional, Lambe, Teresa, additional, Adlou, Syed, additional, Aley, Robert, additional, Ali, Aabidah, additional, Anslow, Rachel, additional, Baker, Megan, additional, Baker, Phillip, additional, Barrett, Jordan R., additional, Bates, Louise, additional, Beadon, Kirsten, additional, Beckley, Rebecca, additional, Bell, Jonathan, additional, Bellamy, Duncan, additional, Beveridge, Amy, additional, Bissett, Cameron, additional, Blackwell, Luke, additional, Bletchly, Heather, additional, Boyd, Amy, additional, Bridges-Webb, Alice, additional, Brown, Charlie, additional, Byard, Nicholas, additional, Camara, Susana, additional, Cifuentes Gutierrez, Liliana, additional, Collins, Andrea M., additional, Cooper, Rachel, additional, Crocker, Wendy E.M., additional, Darton, Thomas C., additional, Davies, Hannah, additional, Davies, Judith, additional, Demissie, Tesfaye, additional, Di Maso, Claudio, additional, Dinesh, Tanya, additional, Donnellan, Francesca R., additional, Douglas, Alexander D., additional, Drake-Brockman, Rachael, additional, Duncan, Christopher J.A., additional, Elias, Sean C., additional, Emary, Katherine R.W., additional, Ghulam Farooq, Mutjaba, additional, Faust, Saul N., additional, Felle, Sally, additional, Ferreira, Daniela, additional, Ferreira Da Silva, Carla, additional, Finn, Adam, additional, Ford, Karen J., additional, Francis, Emma, additional, Furze, Julie, additional, Fuskova, Michelle, additional, Galiza, Eva, additional, Gibertoni Cruz, Ana, additional, Godfrey, Leila, additional, Goodman, Anna L., additional, Green, Catherine, additional, Green, Christopher A., additional, Greenwood, Nicola, additional, Harrison, Daisy, additional, Hart, Thomas C., additional, Hawkins, Sophia, additional, Heath, Paul T., additional, Hill, Helen, additional, Hillson, Kushalinii, additional, Horsington, Bryn, additional, Hou, Mimi M., additional, Howe, Elizabeth, additional, Howell, Nicola, additional, Joe, Carina, additional, Jones, Elizabeth, additional, Kasanyinga, Mwila, additional, Keen, Jade, additional, Kelly, Sarah, additional, Kerr, David, additional, Khan, Liaquat, additional, Khozoee, Baktash, additional, Kinch, Jasmin, additional, Kinch, Patrick, additional, Koleva, Stanislava, additional, Kwok, Jonathan, additional, Larkworthy, Colin W., additional, Lawrie, Alison M., additional, Lazarus, Rajeka, additional, Lees, Emily A., additional, Li, Grace, additional, Libri, Vincenzo, additional, Lillie, Patrick J., additional, Linder, Aline, additional, Long, Fei, additional, Lopez Ramon, Raquel, additional, Mabbett, Reece, additional, Makinson, Rebecca, additional, Marinou, Spyridoula, additional, Marlow, Emma, additional, Marshall, Julia L., additional, Mazur, Olga, additional, McEwan, Joanne, additional, McGregor, Alastair C., additional, Mokaya, Jolynne, additional, Morey, Ella, additional, Morshead, Gertraud, additional, Morter, Richard, additional, Muller, Jilly, additional, Mweu, Philomena, additional, Noristani, Rabiullah, additional, Owino, Nelly, additional, Polo Peralta Alvarez, Marco, additional, Platt, Abigail, additional, Pollock, Katrina M., additional, Poulton, Ian, additional, Provstgaard-Morys, Samuel, additional, Pulido-Gomez, David, additional, Rajan, Matthew, additional, Ramos Lopez, Fernando, additional, Ritchie, Adam, additional, Roberts, Hannah, additional, Rollier, Christine, additional, Rudiansyah, Indra, additional, Sanders, Katherine, additional, Saunders, Jack E., additional, Seddiqi, Samiullah, additional, Sharpe, Hannah R., additional, Shaw, Robert, additional, Silva-Reyes, Laura, additional, Singh, Nisha, additional, Smith, David J., additional, Smith, Catherine C., additional, Smith, Andrew, additional, Spencer, Alexandra J., additional, Stuart, Arabella S.V., additional, Sutherland, Rebecca, additional, Szigeti, Anna, additional, Tang, Karly, additional, Thomas, Merin, additional, Thomas, Tonia M., additional, Thompson, Amber, additional, Thomson, Emma C., additional, Török, Estée M., additional, Toshner, Mark, additional, Tran, Nguyen, additional, Trivett, Rose, additional, Turnbull, Iain, additional, Turner, Cheryl, additional, Turner, David P.J., additional, Ulaszewska, Marta, additional, Vichos, Iason, additional, Walker, Laura, additional, Watson, Marion E., additional, Whelan, Conor, additional, White, Rachel, additional, Williams, Sarah J., additional, Williams, Christopher J.A., additional, Wright, Daniel, additional, and Yao, Andy, additional

Published
2021
Full Text
View/download PDF

38. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Author

Frater, John, primary, Ewer, Katie J, additional, Ogbe, Ane, additional, Pace, Mathew, additional, Adele, Sandra, additional, Adland, Emily, additional, Alagaratnam, Jasmini, additional, Aley, Parvinder K, additional, Ali, Mohammad, additional, Ansari, M Azim, additional, Bara, Anna, additional, Bittaye, Mustapha, additional, Broadhead, Samantha, additional, Brown, Anthony, additional, Brown, Helen, additional, Cappuccini, Federica, additional, Cooney, Enya, additional, Dejnirattisai, Wanwisa, additional, Dold, Christina, additional, Fairhead, Cassandra, additional, Fok, Henry, additional, Folegatti, Pedro M, additional, Fowler, Jamie, additional, Gibbs, Charlotte, additional, Goodman, Anna L, additional, Jenkin, Daniel, additional, Jones, Mathew, additional, Makinson, Rebecca, additional, Marchevsky, Natalie G, additional, Mujadidi, Yama F, additional, Nguyen, Hanna, additional, Parolini, Lucia, additional, Petersen, Claire, additional, Plested, Emma, additional, Pollock, Katrina M, additional, Ramasamy, Maheshi N, additional, Rhead, Sarah, additional, Robinson, Hannah, additional, Robinson, Nicola, additional, Rongkard, Patpong, additional, Ryan, Fiona, additional, Serrano, Sonia, additional, Tipoe, Timothy, additional, Voysey, Merryn, additional, Waters, Anele, additional, Zacharopoulou, Panagiota, additional, Barnes, Eleanor, additional, Dunachie, Susanna, additional, Goulder, Philip, additional, Klenerman, Paul, additional, Screaton, Gavin R, additional, Winston, Alan, additional, Hill, Adrian V S, additional, Gilbert, Sarah C, additional, Pollard, Andrew J, additional, Fidler, Sarah, additional, Fox, Julie, additional, Lambe, Teresa, additional, Watson, Marion E.E., additional, Song, Rinn, additional, Cicconi, Paola, additional, Minassian, Angela M., additional, Bibi, Sagida, additional, Kerridge, Simon, additional, Singh, Nisha, additional, Green, Catherine M., additional, Douglas, Alexander D., additional, Lawrie, Alison M., additional, and Clutterbuck, Elizabeth A., additional

Published
2021
Full Text
View/download PDF

39. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Author

Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Y, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian, Baillie, Vicky L, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth A, Collins, Andrea M, Cutland, Clare L, Darton, Thomas C, Dheda, Keertan, Dold, Christina, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie J, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Joe, Carina CD, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie G, Marshall, Richard P, Mendes, Ana VA, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair, Mujadidi, Yama F, Nana, Anusha, Padayachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Ritchie, Adam J, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, M Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Douglas, Alexander D, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J, and Oxford COVID Vaccine Trial Group

Abstract

Background\ud The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses. In addition, we show the immunogenicity and protection afforded by the first dose, before a booster dose has been offered.MethodsWe present data from three single-blind randomised controlled trials-one phase 1/2 study in the UK (COV001), one phase 2/3 study in the UK (COV002), and a phase 3 study in Brazil (COV003)-and one double-blind phase 1/2 study in South Africa (COV005). As previously described, individuals 18 years and older were randomly assigned 1:1 to receive two standard doses of ChAdOx1 nCoV-19 (5 × 1010 viral particles) or a control vaccine or saline placebo. In the UK trial, a subset of participants received a lower dose (2·2 × 1010 viral particles) of the ChAdOx1 nCoV-19 for the first dose. The primary outcome was virologically confirmed symptomatic COVID-19 disease, defined as a nucleic acid amplification test (NAAT)-positive swab combined with at least one qualifying symptom (fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia) more than 14 days after the second dose. Secondary efficacy analyses included cases occuring at least 22 days after the first dose. Antibody responses measured by immunoassay and by pseudovirus neutralisation were exploratory outcomes. All cases of COVID-19 with a NAAT-positive swab were adjudicated for inclusion in the analysis by a masked independent endpoint review committee. The primary analysis included all participants who were SARS-CoV-2 N protein seronegative at baseline, had had at least 14 days of follow-up after the second dose, and had no evidence of previous SARS-CoV-2 infection from NAAT swabs. Safety was assessed in all participants who received at least one dose. The four trials are registered at ISRCTN89951424 (COV003) and ClinicalTrials.gov, NCT04324606 (COV001), NCT04400838 (COV002), and NCT04444674 (COV005).FindingsBetween April 23 and Dec 6, 2020, 24 422 participants were recruited and vaccinated across the four studies, of whom 17 178 were included in the primary analysis (8597 receiving ChAdOx1 nCoV-19 and 8581 receiving control vaccine). The data cutoff for these analyses was Dec 7, 2020. 332 NAAT-positive infections met the primary endpoint of symptomatic infection more than 14 days after the second dose. Overall vaccine efficacy more than 14 days after the second dose was 66·7% (95% CI 57·4-74·0), with 84 (1·0%) cases in the 8597 participants in the ChAdOx1 nCoV-19 group and 248 (2·9%) in the 8581 participants in the control group. There were no hospital admissions for COVID-19 in the ChAdOx1 nCoV-19 group after the initial 21-day exclusion period, and 15 in the control group. 108 (0·9%) of 12 282 participants in the ChAdOx1 nCoV-19 group and 127 (1·1%) of 11 962 participants in the control group had serious adverse events. There were seven deaths considered unrelated to vaccination (two in the ChAdOx1 nCov-19 group and five in the control group), including one COVID-19-related death in one participant in the control group. Exploratory analyses showed that vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 after vaccination was 76·0% (59·3-85·9). Our modelling analysis indicated that protection did not wane during this initial 3-month period. Similarly, antibody levels were maintained during this period with minimal waning by day 90 (geometric mean ratio [GMR] 0·66 [95% CI 0·59-0·74]). In the participants who received two standard doses, after the second dose, efficacy was higher in those with a longer prime-boost interval (vaccine efficacy 81·3% [95% CI 60·3-91·2] at ≥12 weeks) than in those with a short interval (vaccine efficacy 55·1% [33·0-69·9] at InterpretationThe results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose.FundingUK Research and Innovation, National Institutes of Health Research (NIHR), The Coalition for Epidemic Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Published
2021

40. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Author

Voysey, Merryn, Clemens, Sue Ann Costa, Madhi, Shabir A., Weckx, Lily Y., Folegatti, Pedro M., Aley, Parvinder K., Angus, Brian, Baillie, Vicky L., Barnabas, Shaun L., Bhorat, Qasim E., Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Collins, Andrea M., Colin-Jones, Rachel, Cutland, Clare L., Darton, Thomas C., Dheda, Keertan, Duncan, Christopher J.A., Emary, Katherine R.W., Ewer, Katie J., Fairlie, Lee, Faust, Saul N., Feng, Shuo, Ferreira, Daniela M., Finn, Adam, Goodman, Anna L., Green, Catherine M., Green, Christopher A., Heath, Paul T., Hill, Catherine, Hill, Helen, Hirsch, Ian, Hodgson, Susanne H.C., Izu, Alane, Jackson, Susan, Jenkin, Daniel, Joe, Carina C.D., Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Lawrie, Alison M., Lelliott, Alice, Libri, Vincenzo, Lillie, Patrick J., Mallory, Raburn, Mendes, Ana V.A., Milan, Eveline P., Minassian, Angela M., McGregor, Alastair, Morrison, Hazel, Mujadidi, Yama F., Nana, Anusha, O'Reilly, Peter J., Padayachee, Sherman D., Pittella, Ana, Plested, Emma, Pollock, Katrina M., Ramasamy, Maheshi N., Rhead, Sarah, Schwarzbold, Alexandre V., Singh, Nisha, Smith, Andrew, Song, Rinn, Snape, Matthew D., Sprinz, Eduardo, Sutherland, Rebecca K., Tarrant, Richard, Thomson, Emma C., Toshner, Mark, Turner, David P.J., Vekemans, Johan, Villafana, Tonya L., Watson, Marion E.E., Williams, Christopher J., Douglas, Alexander D., Hill, Adrian V.S., Lambe, Teresa, Gilbert, Sarah C., Pollard, Andrew J., Aban, Marites, Abayomi, Fatola, Abeyskera, Kushala, Aboagye, Jeremy, Adam, Matthew, Adams, Kirsty, Adamson, James, Adelaja, Yemi A., Adlou, Syed, Ahmed, Khatija, Akhalwaya, Yasmeen, Akhalwaya, Saajida, Alcock, Andrew, Ali, Aabidah, Allen, Elizabeth R., Allen, Lauren, Almeida, Thamires C.D.S.C., and Alves, Mariana P.S.

Subjects
General Medicine
Abstract

© 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Published
2021

41. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Author

Ewer, Katie J., Barrett, Jordan R., Belij-Rammerstorfer, Sandra, Sharpe, Hannah, Makinson, Rebecca, Morter, Richard, Flaxman, Amy, Wright, Daniel, Bellamy, Duncan, Bittaye, Mustapha, Dold, Christina, Provine, Nicholas M., Aboagye, Jeremy, Fowler, Jamie, Silk, Sarah E., Alderson, Jennifer, Aley, Parvinder K., Angus, Brian, Berrie, Eleanor, Bibi, Sagida, Cicconi, Paola, Clutterbuck, Elizabeth A., Chelysheva, Irina, Folegatti, Pedro M., Fuskova, Michelle, Green, Catherine M., Jenkin, Daniel, Kerridge, Simon, Lawrie, Alison, Minassian, Angela M., Moore, Maria, Mujadidi, Yama, Plested, Emma, Poulton, Ian, Ramasamy, Maheshi N., Robinson, Hannah, Song, Rinn, Snape, Matthew D., Tarrant, Richard, Voysey, Merryn, Watson, Marion E. E., Douglas, Alexander D., Hill, Adrian V. S., Gilbert, Sarah C., Pollard, Andrew J., Lambe, Teresa, Ali, Aabidah, Allen, Elizabeth, Baker, Megan, Barnes, Eleanor, Borthwick, Nicola, Boyd, Amy, Brown-O’Sullivan, Charlie, Burgoyne, Joshua, Byard, Nicholas, Puig, Ingrid Cabrera, Cappuccini, Federica, Cho, Jee-Sun, Clark, Elizabeth, Crocker, Wendy E. M., Datoo, Mehreen S., Davies, Hannah, Donnellan, Francesca R., Dunachie, Susanna Jane, Edwards, Nick J., Elias, Sean C., Furze, Julie, Gilbride, Ciaran, Gorini, Giacomo, Gupta, Gaurav, Harris, Stephanie A., Hodgson, Susanne H. C., Hou, Mimi M., Jackson, Susan, Jones, Kathryn, Kailath, Reshma, King, Lloyd, Larkworthy, Colin W., Li, Yuanyuan, Lias, Amelia M., Linder, Aline, Lipworth, Samuel, Ramon, Raquel Lopez, Madhavan, Meera, Marlow, Emma, Marshall, Julia L., Mentzer, Alexander J., Morrison, Hazel, Moya, Nathifa, Mukhopadhyay, Ekta, Noé, Andrés, Nugent, Fay L., Pipini, Dimitra, Pulido-Gomez, David, Lopez, Fernando Ramos, Ritchie, Adam John, Rudiansyah, Indra, Salvador, Stephannie, Sanders, Helen, Satti, Iman, Shea, Adam, Silk, Sarah, Spencer, Alexandra J., Tanner, Rachel, Taylor, Iona Jennifer, Themistocleous, Yrene, Thomas, Merin, Tran, Nguyen, Truby, Adam, Turner, Cheryl, Turner, Nicola, Ulaszewska, Marta, Worth, Andrew T., Kingham-Page, Lucy, Alvarez, Marco Polo Peralta, Anslow, Rachel, Bates, Louise, Beadon, Kirsten, Beckley, Rebecca, Beveridge, Amy, Bijker, Else Margreet, Blackwell, Luke, Burbage, Jamie, Camara, Susana, Carr, Melanie, Colin-Jones, Rachel, Cooper, Rachel, Cunningham, Christina J., Demissie, Tesfaye, Maso, Claudio Di, Douglas, Naomi, Drake-Brockman, Rachael, Drury, Ruth Elizabeth, Emary, Katherine R. W., Felle, Sally, Feng, Shuo, Silva, Carla Ferreira Da, Ford, Karen J., Francis, Emma, Gracie, Lara, Hamlyn, Joseph, Hanumunthadu, Brama, Harrison, Daisy, Hart, Thomas C., Hawkins, Sophia, Hill, Jennifer, Howe, Elizabeth, Howell, Nicola, Jones, Elizabeth, Keen, Jade, Kelly, Sarah, Kerr, David, Khan, Liaquat, Kinch, Jasmin, Koleva, Stanislava, Lees, Emily A., Lelliott, Alice, Liu, Xinxue, Marchevsky, Natalie G., Marinou, Spyridoula, McEwan, Joanne, Morey, Ella, Morshead, Gertraud, Muller, Jilly, Munro, Claire, Murphy, Sarah, Mweu, Philomena, Nuthall, Elizabeth, O’Brien, Katie, O’Connor, Daniel, O’Reilly, Peter John, Oguti, Blanché, Osborne, Piper, Owino, Nelly, Parker, Kaye, Pfafferott, Katja, Phillips, Daniel, Provstgaard-Morys, Samuel, Ratcliffe, Helen, Rawlinson, Thomas, Rhead, Sarah, Roberts, Hannah, Sanders, Katherine, Silva-Reyes, Laura, Rollier, Christine S., Smith, Catherine C., Smith, David J., Stockdale, Lisa, Szigeti, Anna, Thomas, Tonia M., Thompson, Amber, Tomic, Adriana, Tonks, Susan, Varughese, Rachel, Verheul, Marije K., Vichos, Iason, Walker, Laura, White, Caroline, White, Rachel, Yao, Xin Li, Conlon, Christopher P., Frater, John, Cifuentes, Liliana, Baleanu, Ioana, Bolam, Emma, Boland, Elena, Brenner, Tanja, Damratoski, Brad E., Datta, Chandra, Muhanna, Omar El, Fisher, Richard, Galian-Rubio, Pablo, Hodges, Gina, Jackson, Frederic, Liu, Shuchang, Loew, Lisa, Morgans, Roisin, Morris, Susan Jane, Olchawski, Vicki, Oliveria, Catarina, Parracho, Helena, Pabon, Emilia Reyes, Tahiri-Alaoui, Abdessamad, Taylor, Keja, Williams, Paul, Zizi, Dalila, Arbe-Barnes, Edward H., Baker, Philip, Batten, Alexander, Downing, Charlotte, Drake, Jonathan, English, Marcus Rex, Henry, John Aaron, Iveson, Poppy, Killen, Annabel, King, Thomas B., Larwood, Jessica P. J., Mallett, Garry, Mansatta, Kushal, Mirtorabi, Neginsadat, Patrick-Smith, Maia, Perring, James, Radia, Kajal, Roche, Sophie, Schofield, Ella, Naude, Rebecca te Water, Towner, James, Baker, Natalie, Bewley, Kevin R., Brunt, Emily, Buttigieg, Karen R., Carroll, Miles W., Charlton, Sue, Coombes, Naomi S., Elmore, Michael J., Godwin, Kerry, Hallis, Bassam, Knott, Daniel, McInroy, Lorna, Shaik, Imam, Thomas, Kelly, Tree, Julia A., Blundell, Caitlin L., Cao, Michelangelo, Kelly, Dearbhla, Schmid, Annina, Skelly, Donal T., Themistocleous, Andreas, Dong, Tao, Field, Samantha, Hamilton, Elizabeth, Kelly, Elizabeth, Klenerman, Paul, Knight, Julian C., Lie, Yolanda, Petropoulos, Christos, Sedik, Cynthia, Wrin, Terri, Meddaugh, Gretchen, Peng, Yanchun, Screaton, Gavin, and Stafford, Elizabeth

Subjects
0301 basic medicine, biology, business.industry, T cell, Immunogenicity, General Medicine, Vaccine efficacy, General Biochemistry, Genetics and Molecular Biology, Vaccination, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, Immune system, Immunity, 030220 oncology & carcinogenesis, Immunology, biology.protein, medicine, Cytotoxic T cell, Antibody, business
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed1. Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses2 and might reduce the potential for disease enhancement3. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection4. Studies of patients infected with SARS-CoV-2 have suggested a protective role for both humoral and cell-mediated immune responses in recovery from COVID-19 (refs. 5,6). ChAdOx1 nCoV-19 (AZD1222) is a candidate SARS-CoV-2 vaccine comprising a replication-deficient simian adenovirus expressing full-length SARS-CoV-2 spike protein. We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)7 given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. Here we describe, in detail, exploratory analyses of the immune responses in adults, aged 18–55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 in this trial, demonstrating an induction of a Th1-biased response characterized by interferon-γ and tumor necrosis factor-α cytokine secretion by CD4+ T cells and antibody production predominantly of IgG1 and IgG3 subclasses. CD8+ T cells, of monofunctional, polyfunctional and cytotoxic phenotypes, were also induced. Taken together, these results suggest a favorable immune profile induced by ChAdOx1 nCoV-19 vaccine, supporting the progression of this vaccine candidate to ongoing phase 2/3 trials to assess vaccine efficacy. A single dose of the ChAdOx1 nCoV-19 vaccine elicits antibodies and cytokine-producing T cells that might help control or prevent SARS-CoV-2 infection.

Published
2020
Full Text
View/download PDF

42. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Author

Emary, Katherine R. W., primary, Golubchik, Tanya, additional, Aley, Parvinder K., additional, Ariani, Cristina V., additional, Angus, Brian John, additional, Bibi, Sagida, additional, Blane, Beth, additional, Bonsall, David, additional, Cicconi, Paola, additional, Charlton, Sue, additional, Clutterbuck, Elizabeth, additional, Collins, Andrea M., additional, Cox, Tony, additional, Darton, Thomas, additional, Dold, Christina, additional, Douglas, Alexander D., additional, Duncan, Christopher J. A., additional, Ewer, Katie, additional, Flaxman, Amy, additional, Faust, Saul N., additional, Ferreira, Daniela M., additional, Feng, Shuo, additional, Finn, Adam, additional, Folegatti, Pedro M., additional, Fuskova, Michelle, additional, Galiza, Eva, additional, Goodman, Anna L., additional, Green, Catherine M., additional, Green, Christopher A., additional, Greenland, Melanie, additional, Hallis, Bassam, additional, Heath, Paul T., additional, Hay, Jodie, additional, Hill, Helen C., additional, Jenkin, Daniel, additional, Kerridge, Simon, additional, Lazarus, Rajeka, additional, Libri, Vincenzo, additional, Lillie, Patrick J., additional, Ludden, Catherine, additional, Marchevsky, Natalie G., additional, Minassian, Angela M., additional, McGregor, Alastair C., additional, Farooq Mujadidi, Yama, additional, Phillips, Daniel J., additional, Plested, Emma, additional, Pollock, Katrina M., additional, Robinson, Hannah, additional, Smith, Andrew, additional, Song, Rinn, additional, Snape, Matthew D., additional, Sutherland, Rebecca K., additional, Thomson, Emma C., additional, Toshner, Mark, additional, Turner, David P. J., additional, Vekemans, Johan, additional, Villafana, Tonya L., additional, Williams, Christopher J., additional, Hill, Adrian V. S., additional, Lambe, Teresa, additional, Gilbert, Sarah C., additional, Voysey, Merryn, additional, Ramasamy, Maheshi N., additional, Pollard, Andrew, additional, and Group, Oxford COVID Vaccine Trial, additional

Published
2021
Full Text
View/download PDF

43. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Author

Voysey, Merryn, primary, Costa Clemens, Sue Ann, additional, Madhi, Shabir A., additional, Weckx, Lily Yin, additional, Folegatti, Pedro M., additional, Aley, Parvinder K., additional, Angus, Brian John, additional, Baillie, Vicky, additional, Barnabas, Shaun L., additional, Bhorat, Qasim E., additional, Bibi, Sagida, additional, Briner, Carmen, additional, Cicconi, Paola, additional, Clutterbuck, Elizabeth, additional, Collins, Andrea M., additional, Cutland, Clare, additional, Darton, Thomas, additional, Dheda, Keertan, additional, Douglas, Alexander D., additional, Duncan, Christopher J. A., additional, Emary, Katherine R. W., additional, Ewer, Katie, additional, Flaxman, Amy, additional, Fairlie, Lee, additional, Faust, Saul N., additional, Feng, Shuo, additional, Ferreira, Daniela M., additional, Finn, Adam, additional, Galiza, Eva, additional, Goodman, Anna L., additional, Green, Catherine M., additional, Green, Christopher A., additional, Greenland, Melanie, additional, Hill, Catherine, additional, Hill, Helen C., additional, Hirsch, Ian, additional, Izu, Alane, additional, Jenkin, Daniel, additional, Kerridge, Simon, additional, Koen, Anthonet, additional, Kwatra, Gaurav, additional, Lazarus, Rajeka, additional, Libri, Vincenzo, additional, Lillie, Patrick J., additional, Marchevsky, Natalie G., additional, Marshall, Richard P., additional, Mendes, Ana Verena Almeida, additional, Milan, Eveline P., additional, Minassian, Angela M., additional, McGregor, Alastair C., additional, Farooq Mujadidi, Yama, additional, Nana, Anusha, additional, Payadachee, Sherman D., additional, Phillips, Daniel J., additional, Pittella, Ana, additional, Plested, Emma, additional, Pollock, Katrina M., additional, Ramasamy, Maheshi N., additional, Robinson, Hannah, additional, Schwarzbold, Alexandre V., additional, Smith, Andrew, additional, Song, Rinn, additional, Snape, Matthew D., additional, Sprinz, Eduardo, additional, Sutherland, Rebecca K., additional, Thomson, Emma C., additional, Torok, Mili, additional, Toshner, Mark, additional, Turner, David P. J., additional, Vekemans, Johan, additional, Villafana, Tonya L., additional, White, Thomas, additional, Williams, Christopher J., additional, Hill, Adrian V. S., additional, Lambe, Teresa, additional, Gilbert, Sarah C., additional, Pollard, Andrew, additional, and Group, Oxford COVID Vaccine Trial, additional

Published
2021
Full Text
View/download PDF

44. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Author

Ramasamy, Maheshi N, primary, Minassian, Angela M, additional, Ewer, Katie J, additional, Flaxman, Amy L, additional, Folegatti, Pedro M, additional, Owens, Daniel R, additional, Voysey, Merryn, additional, Aley, Parvinder K, additional, Angus, Brian, additional, Babbage, Gavin, additional, Belij-Rammerstorfer, Sandra, additional, Berry, Lisa, additional, Bibi, Sagida, additional, Bittaye, Mustapha, additional, Cathie, Katrina, additional, Chappell, Harry, additional, Charlton, Sue, additional, Cicconi, Paola, additional, Clutterbuck, Elizabeth A, additional, Colin-Jones, Rachel, additional, Dold, Christina, additional, Emary, Katherine R W, additional, Fedosyuk, Sofiya, additional, Fuskova, Michelle, additional, Gbesemete, Diane, additional, Green, Catherine, additional, Hallis, Bassam, additional, Hou, Mimi M, additional, Jenkin, Daniel, additional, Joe, Carina C D, additional, Kelly, Elizabeth J, additional, Kerridge, Simon, additional, Lawrie, Alison M, additional, Lelliott, Alice, additional, Lwin, May N, additional, Makinson, Rebecca, additional, Marchevsky, Natalie G, additional, Mujadidi, Yama, additional, Munro, Alasdair P S, additional, Pacurar, Mihaela, additional, Plested, Emma, additional, Rand, Jade, additional, Rawlinson, Thomas, additional, Rhead, Sarah, additional, Robinson, Hannah, additional, Ritchie, Adam J, additional, Ross-Russell, Amy L, additional, Saich, Stephen, additional, Singh, Nisha, additional, Smith, Catherine C, additional, Snape, Matthew D, additional, Song, Rinn, additional, Tarrant, Richard, additional, Themistocleous, Yrene, additional, Thomas, Kelly M, additional, Villafana, Tonya L, additional, Warren, Sarah C, additional, Watson, Marion E E, additional, Douglas, Alexander D, additional, Hill, Adrian V S, additional, Lambe, Teresa, additional, Gilbert, Sarah C, additional, Faust, Saul N, additional, Pollard, Andrew J, additional, Aboagye, Jeremy, additional, Adams, Kelly, additional, Ali, Aabidah, additional, Allen, Elizabeth R., additional, Allen, Lauren, additional, Allison, Jennifer L., additional, Andritsou, Foteini, additional, Anslow, Rachel, additional, Arbe-Barnes, Edward H., additional, Baker, Megan, additional, Baker, Natalie, additional, Baker, Philip, additional, Baleanu, Ioana, additional, Barker, Debbie, additional, Barnes, Eleanor, additional, Barrett, Jordan R., additional, Barrett, Kelly, additional, Bates, Louise, additional, Batten, Alexander, additional, Beadon, Kirsten, additional, Beckley, Rebecca, additional, Bellamy, Duncan, additional, Berg, Adam, additional, Bermejo, Laura, additional, Berrie, Eleanor, additional, Beveridge, Amy, additional, Bewley, Kevin, additional, Bijker, Else M., additional, Birch, Geeta, additional, Blackwell, Luke, additional, Bletchly, Heather, additional, Blundell, Caitlin L., additional, Blundell, Susannah R., additional, Bolam, Emma, additional, Boland, Elena, additional, Bormans, Daan, additional, Borthwick, Nicola, additional, Boukas, Konstantinos, additional, Bower, Thomas, additional, Bowring, Francesca, additional, Boyd, Amy, additional, Brenner, Tanja, additional, Brown, Phillip, additional, Brown-O'Sullivan, Charlie, additional, Bruce, Scott, additional, Brunt, Emily, additional, Burbage, Jamie, additional, Burgoyne, Joshua, additional, Buttigieg, Karen R., additional, Byard, Nicholas, additional, Cabera Puig, Ingrid, additional, Camara, Susana, additional, Cao, Michelangelo, additional, Cappuccini, Federica, additional, Carr, Melanie, additional, Carroll, Miles W., additional, Cashen, Paul, additional, Cavey, Ana, additional, Chadwick, Jim, additional, Challis, Ruth, additional, Chapman, David, additional, Charles, David, additional, Chelysheva, Irina, additional, Cho, Jee-Sun, additional, Cifuentes, Liliana, additional, Clark, Elizabeth, additional, Collins, Sarah, additional, Conlon, Christopher P., additional, Coombes, Naomi S., additional, Cooper, Rachel, additional, Cooper, Cushla, additional, Crocker, Wendy E.M., additional, Crosbie, Sarah, additional, Cullen, Dan, additional, Cunningham, Christina, additional, Cuthbertson, Fiona, additional, Datoo, Brad E., additional, Dando, Lynne, additional, Datoo, Mehreen S., additional, Datta, Chandrabali, additional, Davies, Hannah, additional, Davies, Sarah, additional, Davis, Elizabeth J., additional, Davis, Judith, additional, Dearlove, David, additional, Demissie, Tesfaye, additional, Di Marco, Stefania, additional, Di Maso, Claudio, additional, DiTirro, Danielle, additional, Docksey, Claire, additional, Dong, Tao, additional, Donnellan, Francesca R., additional, Douglas, Naomi, additional, Downing, Charlotte, additional, Drake, Jonathan, additional, Drake-Brockman, Rachael, additional, Drury, Ruth E., additional, Dunachie, Susanna J., additional, Edwards, Christopher J., additional, Edwards, Nick J., additional, El Muhanna, Omar, additional, Elias, Sean C., additional, Elliott, Ryan S., additional, Elmore, Michael J., additional, English, Marcus Rex, additional, Felle, Sally, additional, Feng, Shuo, additional, Ferreira Da Silva, Carla, additional, Field, Samantha, additional, Fisher, Richard, additional, Fixmer, Carine, additional, Ford, Karen J., additional, Fowler, Jamie, additional, Francis, Emma, additional, Frater, John, additional, Furze, Julie, additional, Galian-Rubio, Pablo, additional, Galloway, Celine, additional, Garlant, Harriet, additional, Gavrila, Madita, additional, Gibbons, Felicity, additional, Gibbons, Karyna, additional, Gilbride, Ciaran, additional, Gill, Hardeep, additional, Godwin, Kerry, additional, Gordon-Quayle, Katherine, additional, Gorini, Giacomo, additional, Goulston, Lyndsey, additional, Grabau, Caroline, additional, Gracie, Lara, additional, Graham, Nichola, additional, Greenwood, Nicola, additional, Griffiths, Oliver, additional, Gupta, Gaurav, additional, Hamilton, Elizabeth, additional, Hanumunthadu, Brama, additional, Harris, Stephanie A., additional, Harris, Tara, additional, Harrison, Daisy, additional, Hart, Thomas C., additional, Hartnell, Birgit, additional, Haskell, Louise, additional, Hawkins, Sophia, additional, Henry, John Aaron, additional, Hermosin Herrera, Macarena, additional, Hill, David, additional, Hill, Jennifer, additional, Hodges, Gina, additional, Hodgson, Susanne H.C., additional, Horton, Katie L., additional, Howe, Elizabeth, additional, Howell, Nicola, additional, Howes, Jessica, additional, Huang, Ben, additional, Humphreys, Jonathan, additional, Humphries, Holly E., additional, Iveson, Poppy, additional, Jackson, Frederic, additional, Jackson, Susan, additional, Jauregui, Sam, additional, Jeffers, Helen, additional, Jones, Bryony, additional, Jones, Christine E., additional, Jones, Elizabeth, additional, Jones, Kathryn, additional, Joshi, Amar, additional, Kailath, Reshma, additional, Keen, Jade, additional, Kelly, Dearbhla M., additional, Kelly, Sarah, additional, Kelly, Debbie, additional, Kerr, David, additional, Khan, Liaquat, additional, Khozoee, Baktash, additional, Killen, Annabel, additional, Kinch, Jasmin, additional, King, Lloyd D.W., additional, King, Thomas B., additional, Kingham, Lucy, additional, Klenerman, Paul, additional, Knight, Julian C., additional, Knott, Daniel, additional, Koleva, Stanislava, additional, Lang, Gail, additional, Larkworthy, Colin W., additional, Larwood, Jessica P.J., additional, Law, Rebecca, additional, Lee, Arlene, additional, Lee, Kim Y.N., additional, Lees, Emily A., additional, Leung, Stephanie, additional, Li, Yuanyuan, additional, Lias, Amelia M., additional, Linder, Aline, additional, Lipworth, Samuel, additional, Liu, Shuchang, additional, Liu, Xinxue, additional, Lloyd, Stephanie, additional, Loew, Lisa, additional, Lopez Ramon, Raquel, additional, Madhavan, Meera, additional, Mainwaring, David O., additional, Mallett, Garry, additional, Mansatta, Kushal, additional, Marinou, Spyridoula, additional, Marius, Phedra, additional, Marlow, Emma, additional, Marriott, Paula, additional, Marshall, Julia L., additional, Martin, Jane, additional, Masters, Shauna, additional, McEwan, Joanne, additional, McGlashan, Joanna L., additional, McInroy, Lorna, additional, McRobert, Nicky, additional, Megson, Clare, additional, Mentzer, Alexander J., additional, Mirtorabi, Neginsadat, additional, Mitton, Celia, additional, Moore, Maria, additional, Moran, Marni, additional, Morey, Ella, additional, Morgans, Róisín, additional, Morris, Susan J., additional, Morrison, Hazel Morrison, additional, Morshead, Gertraud, additional, Morter, Richard, additional, Moya, Nathifa A., additional, Mukhopadhyay, Ekta, additional, Muller, Jilly, additional, Munro, Claire, additional, Murphy, Sarah, additional, Mweu, Philomena, additional, Noé, Andrés, additional, Nugent, Fay L., additional, O'Brien, Katie, additional, O'Connor, Daniel, additional, Oguti, Blanché, additional, Olchawski, Victoria, additional, Oliveira, Catarina, additional, O'Reilly, Peter John, additional, Osborne, Piper, additional, Owen, Lydia, additional, Owino, Nelly, additional, Papageorgiou, Panagiotis, additional, Parracho, Helena, additional, Parsons, Karen, additional, Patel, Bhumika, additional, Patrick-Smith, Maia, additional, Peng, Yanchun, additional, Penn, Elizabeth J., additional, Peralta-Alvarez, Marco Polo, additional, Perring, James, additional, Petropoulos, Christos, additional, Phillips, Daniel J., additional, Pipini, Dimitra, additional, Pollard, Samuel, additional, Poulton, Ian, additional, Pratt, Danny, additional, Presland, Laura, additional, Proud, Pamela C., additional, Provstgaard-Morys, Samuel, additional, Pueschel, Sophie, additional, Pulido, David, additional, Rabara, Ria, additional, Radia, Kajal, additional, Rajapaska, Durga, additional, Ramos Lopez, Fernando, additional, Ratcliffe, Helen, additional, Rayhan, Sara, additional, Rees, Byron, additional, Reyes Pabon, Emilia, additional, Roberts, Hannah, additional, Robertson, Isla, additional, Roche, Sophie, additional, Rollier, Christine S., additional, Romani, Rossana, additional, Rose, Zoe, additional, Rudiansyah, Indra, additional, Sabheha, Sabeha, additional, Salvador, Stephannie, additional, Sanders, Helen, additional, Sanders, Katherine, additional, Satti, Iman, additional, Sayce, Chloe, additional, Schmid, Annina B., additional, Schofield, Ella, additional, Screaton, Gavin, additional, Sedik, Cynthia, additional, Seddiqi, Samiullah, additional, Segireddy, Rameswara R., additional, Selby, Beatrice, additional, Shaik, Imam, additional, Sharpe, Hannah R., additional, Shaw, Robert, additional, Shea, Adam, additional, Silk, Sarah, additional, Silva-Reyes, Laura, additional, Skelly, Donal T., additional, Smith, David J., additional, Smith, Daniel C., additional, Smith, Nicholas, additional, Spencer, Alexandra J., additional, Spoors, Louise, additional, Stafford, Elizabeth, additional, Stamford, Imogen, additional, Stockdale, Lisa, additional, Stockley, David, additional, Stockwell, Lisa V., additional, Stokes, Matthew, additional, Strickland, Louise H., additional, Stuart, Arabella, additional, Sulaiman, Sulaiman, additional, Summerton, Eloise, additional, Swash, Zoe, additional, Szigeti, Anna, additional, Tahiri-Alaoui, Abdessamad, additional, Tanner, Rachel, additional, Taylor, Iona, additional, Taylor, Keja, additional, Taylor, Ursula, additional, te Water Naude, Rebecca, additional, Themistocleous, Andreas, additional, Thomas, Merin, additional, Thomas, Tonia M., additional, Thompson, Amber, additional, Thompson, Kevin, additional, Thornton-Jones, Viv, additional, Tinh, Lan, additional, Tomic, Adriana, additional, Tonks, Susan, additional, Towner, James, additional, Tran, Nguyen, additional, Tree, Julian A., additional, Truby, Adam, additional, Turner, Cheryl, additional, Turner, Richard, additional, Ulaszewska, Marta, additional, Varughese, Rachel, additional, Verbart, Dennis, additional, Verheul, Marije K., additional, Vichos, Iason, additional, Walker, Laura, additional, Wand, Matthew E., additional, Watkins, Bridget, additional, Welch, Jessica, additional, West, Alison J., additional, White, Caroline, additional, White, Rachel, additional, Williams, Paul, additional, Woodyer, Mark, additional, Worth, Andrew T., additional, Wright, Daniel, additional, Wrin, Terri, additional, Yao, Xin Li, additional, Zbarcea, Diana-Andreea, additional, and Zizi, Dalila, additional

Published
2020
Full Text
View/download PDF

46. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Author

Folegatti, Pedro M, primary, Ewer, Katie J, additional, Aley, Parvinder K, additional, Angus, Brian, additional, Becker, Stephan, additional, Belij-Rammerstorfer, Sandra, additional, Bellamy, Duncan, additional, Bibi, Sagida, additional, Bittaye, Mustapha, additional, Clutterbuck, Elizabeth A, additional, Dold, Christina, additional, Faust, Saul N, additional, Finn, Adam, additional, Flaxman, Amy L, additional, Hallis, Bassam, additional, Heath, Paul, additional, Jenkin, Daniel, additional, Lazarus, Rajeka, additional, Makinson, Rebecca, additional, Minassian, Angela M, additional, Pollock, Katrina M, additional, Ramasamy, Maheshi, additional, Robinson, Hannah, additional, Snape, Matthew, additional, Tarrant, Richard, additional, Voysey, Merryn, additional, Green, Catherine, additional, Douglas, Alexander D, additional, Hill, Adrian V S, additional, Lambe, Teresa, additional, Gilbert, Sarah C, additional, Pollard, Andrew J, additional, Aboagye, Jeremy, additional, Adams, Kelly, additional, Ali, Aabidah, additional, Allen, Elizabeth, additional, Allison, Jennifer L., additional, Anslow, Rachel, additional, Arbe-Barnes, Edward H., additional, Babbage, Gavin, additional, Baillie, Kenneth, additional, Baker, Megan, additional, Baker, Natalie, additional, Baker, Philip, additional, Baleanu, Ioana, additional, Ballaminut, Juliana, additional, Barnes, Eleanor, additional, Barrett, Jordan, additional, Bates, Louise, additional, Batten, Alexander, additional, Beadon, Kirsten, additional, Beckley, Rebecca, additional, Berrie, Eleanor, additional, Berry, Lisa, additional, Beveridge, Amy, additional, Bewley, Kevin R., additional, Bijker, Else Margreet, additional, Bingham, Tracey, additional, Blackwell, Luke, additional, Blundell, Caitlin L., additional, Bolam, Emma, additional, Boland, Elena, additional, Borthwick, Nicola, additional, Bower, Thomas, additional, Boyd, Amy, additional, Brenner, Tanja, additional, Bright, Philip D., additional, Brown-O'Sullivan, Charlie, additional, Brunt, Emily, additional, Burbage, Jamie, additional, Burge, Sharon, additional, Buttigieg, Karen R., additional, Byard, Nicholas, additional, Cabera Puig, Ingrid, additional, Calvert, Anna, additional, Camara, Susana, additional, Cao, Michelangelo, additional, Cappuccini, Federica, additional, Carr, Melanie, additional, Carroll, Miles W., additional, Carter, Victoria, additional, Cathie, Katrina, additional, Challis, Ruth J., additional, Charlton, Sue, additional, Chelysheva, Irina, additional, Cho, Jee-Sun, additional, Cicconi, Paola, additional, Cifuentes, Liliana, additional, Clark, Helen, additional, Clark, Elizabeth, additional, Cole, Tom, additional, Colin-Jones, Rachel, additional, Conlon, Christopher P., additional, Cook, Aislinn, additional, Coombes, Naomi S., additional, Cooper, Rachel, additional, Cosgrove, Catherine A., additional, Coy, Karen, additional, Crocker, Wendy E.M., additional, Cunningham, Christina J., additional, Damratoski, Brad E., additional, Dando, Lynne, additional, Datoo, Mehreen S., additional, Davies, Hannah, additional, De Graaf, Hans, additional, Demissie, Tesfaye, additional, Di Maso, Claudio, additional, Dietrich, Isabelle, additional, Dong, Tao, additional, Donnellan, Francesca R., additional, Douglas, Naomi, additional, Downing, Charlotte, additional, Drake, Jonathan, additional, Drake-Brockman, Rachael, additional, Drury, Ruth Elizabeth, additional, Dunachie, Susanna Jane, additional, Edwards, Nick J., additional, Edwards, Frances D.L., additional, Edwards, Chris J., additional, Elias, Sean C., additional, Elmore, Michael J., additional, Emary, Katherine R.W., additional, English, Marcus Rex, additional, Fagerbrink, Susanne, additional, Felle, Sally, additional, Feng, Shuo, additional, Field, Samantha, additional, Fixmer, Carine, additional, Fletcher, Clare, additional, Ford, Karen J., additional, Fowler, Jamie, additional, Fox, Polly, additional, Francis, Emma, additional, Frater, John, additional, Furze, Julie, additional, Fuskova, Michelle, additional, Galiza, Eva, additional, Gbesemete, Diane, additional, Gilbride, Ciaran, additional, Godwin, Kerry, additional, Gorini, Giacomo, additional, Goulston, Lyndsey, additional, Grabau, Caroline, additional, Gracie, Lara, additional, Gray, Zoe, additional, Guthrie, Lucy Belle, additional, Hackett, Mark, additional, Halwe, Sandro, additional, Hamilton, Elizabeth, additional, Hamlyn, Joseph, additional, Hanumunthadu, Brama, additional, Harding, Irasha, additional, Harris, Stephanie A., additional, Harris, Andrew, additional, Harrison, Daisy, additional, Harrison, Clare, additional, Hart, Thomas C., additional, Haskell, Louise, additional, Hawkins, Sophia, additional, Head, Ian, additional, Henry, John Aaron, additional, Hill, Jennifer, additional, Hodgson, Susanne H.C., additional, Hou, Mimi M., additional, Howe, Elizabeth, additional, Howell, Nicola, additional, Hutlin, Cecilia, additional, Ikram, Sabina, additional, Isitt, Catherine, additional, Iveson, Poppy, additional, Jackson, Susan, additional, Jackson, Frederic, additional, James, Sir William, additional, Jenkins, Megan, additional, Jones, Elizabeth, additional, Jones, Kathryn, additional, Jones, Christine E., additional, Jones, Bryony, additional, Kailath, Reshma, additional, Karampatsas, Konstantinos, additional, Keen, Jade, additional, Kelly, Sarah, additional, Kelly, Dearbhla, additional, Kerr, David, additional, Kerridge, Simon, additional, Khan, Liaquat, additional, Khan, Uzma, additional, Killen, Annabel, additional, Kinch, Jasmin, additional, King, Thomas B., additional, King, Lloyd, additional, King, Jade, additional, Kingham-Page, Lucy, additional, Klenerman, Paul, additional, Knapper, Francesca, additional, Knight, Julian C., additional, Knott, Daniel, additional, Koleva, Stanislava, additional, Kupke, Alexandra, additional, Larkworthy, Colin W., additional, Larwood, Jessica P.J., additional, Laskey, Anna, additional, Lawrie, Alison M., additional, Lee, Arlene, additional, Ngan Lee, Kim Yee, additional, Lees, Emily A, additional, Legge, Helen, additional, Lelliott, Alice, additional, Lemm, Nana-Marie, additional, Lias, Amelia M., additional, Linder, Aline, additional, Lipworth, Samuel, additional, Liu, Xinxue, additional, Liu, Shuchang, additional, Lopez Ramon, Raquel, additional, Lwin, May, additional, Mabesa, Francesca, additional, Madhavan, Meera, additional, Mallett, Garry, additional, Mansatta, Kushal, additional, Marcal, Ines, additional, Marinou, Spyridoula, additional, Marlow, Emma, additional, Marshall, Julia L., additional, Martin, Jane, additional, McEwan, Joanne, additional, McInroy, Lorna, additional, Meddaugh, Gretchen, additional, Mentzer, Alexander J., additional, Mirtorabi, Neginsadat, additional, Moore, Maria, additional, Moran, Edward, additional, Morey, Ella, additional, Morgan, Victoria, additional, Morris, Susan Jane, additional, Morrison, Hazel, additional, Morshead, Gertraud, additional, Morter, Richard, additional, Mujadidi, Yama F., additional, Muller, Jilly, additional, Munera-Huertas, Tatiana, additional, Munro, Claire, additional, Munro, Alasdair, additional, Murphy, Sarah, additional, Munster, Vincent J., additional, Mweu, Philomena, additional, Noé, Andrés, additional, Nugent, Fay L., additional, Nuthall, Elizabeth, additional, O'Brien, Katie, additional, O'Connor, Daniel, additional, Oguti, Blanché, additional, Oliver, Jennifer L., additional, Oliveira, Catarina, additional, O'Reilly, Peter John, additional, Osborn, Mairead, additional, Osborne, Piper, additional, Owen, Cathy, additional, Owens, Daniel, additional, Owino, Nelly, additional, Pacurar, Mihaela, additional, Parker, Kaye, additional, Parracho, Helena, additional, Patrick-Smith, Maia, additional, Payne, Victoria, additional, Pearce, Jennifer, additional, Peng, Yanchun, additional, Peralta Alvarez, Marco Polo, additional, Perring, James, additional, Pfafferott, Katja, additional, Pipini, Dimitra, additional, Plested, Emma, additional, Pluess-Hall, Helen, additional, Pollock, Katrina, additional, Poulton, Ian, additional, Presland, Laura, additional, Provstgaard-Morys, Samuel, additional, Pulido, David, additional, Radia, Kajal, additional, Ramos Lopez, Fernando, additional, Rand, Jade, additional, Ratcliffe, Helen, additional, Rawlinson, Thomas, additional, Rhead, Sarah, additional, Riddell, Amy, additional, Ritchie, Adam John, additional, Roberts, Hannah, additional, Robson, Joanna, additional, Roche, Sophie, additional, Rohde, Cornelius, additional, Rollier, Christine S., additional, Romani, Rossana, additional, Rudiansyah, Indra, additional, Saich, Stephen, additional, Sajjad, Sara, additional, Salvador, Stephannie, additional, Sanchez Riera, Lidia, additional, Sanders, Helen, additional, Sanders, Katherine, additional, Sapaun, Shari, additional, Sayce, Chloe, additional, Schofield, Ella, additional, Screaton, Gavin, additional, Selby, Beatrice, additional, Semple, Calum, additional, Sharpe, Hannah R., additional, Shaik, Imam, additional, Shea, Adam, additional, Shelton, Holly, additional, Silk, Sarah, additional, Silva-Reyes, Laura, additional, Skelly, Donal T., additional, Smee, Heather, additional, Smith, Catherine C., additional, Smith, David J., additional, Song, Rinn, additional, Spencer, Alexandra J., additional, Stafford, Elizabeth, additional, Steele, Amy, additional, Stefanova, Elena, additional, Stockdale, Lisa, additional, Szigeti, Anna, additional, Tahiri-Alaoui, Abdessamad, additional, Tait, Moira, additional, Talbot, Helen, additional, Tanner, Rachel, additional, Taylor, Iona Jennifer, additional, Taylor, Victoria, additional, Te Water Naude, Rebecca, additional, Thakur, Nazia, additional, Themistocleous, Yrene, additional, Themistocleous, Andreas, additional, Thomas, Merin, additional, Thomas, Tonia M., additional, Thompson, Amber, additional, Thomson-Hill, Samantha, additional, Tomlins, Jennifer, additional, Tonks, Susan, additional, Towner, James, additional, Tran, Nguyen, additional, Tree, Julia A., additional, Truby, Adam, additional, Turkentine, Kate, additional, Turner, Cheryl, additional, Turner, Nicola, additional, Turner, Sally, additional, Tuthill, Toby, additional, Ulaszewska, Marta, additional, Varughese, Rachel, additional, Van Doremalen, Neeltje, additional, Veighey, Kristin, additional, Verheul, Marije K., additional, Vichos, Iason, additional, Vitale, Elia, additional, Walker, Laura, additional, Watson, Marion E.E., additional, Welham, Benjamin, additional, Wheat, Julie, additional, White, Caroline, additional, White, Rachel, additional, Worth, Andrew T., additional, Wright, Danny, additional, Wright, Suzie, additional, Yao, Xin Li, additional, and Yau, Yasmine, additional

Published
2020
Full Text
View/download PDF

48. Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation

Author

Dulal, Pawan, primary, Walters, Adam A, additional, Hawkins, Nicholas, additional, Claridge, Tim DW, additional, Kowal, Katarzyna, additional, Neill, Steven, additional, Russell, Stephen J, additional, Ritchie, Adam, additional, Ashfield, Rebecca, additional, Hill, Adrian VS, additional, and Douglas, Alexander D, additional

Published
2020
Full Text
View/download PDF

49. Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components

Author

Fedosyuk, Sofiya, primary, Merritt, Thomas, additional, Peralta-Alvarez, Marco Polo, additional, Morris, Susan J, additional, Lam, Ada, additional, Laroudie, Nicolas, additional, Kangokar, Anilkumar, additional, Wright, Daniel, additional, Warimwe, George M, additional, Angell-Manning, Phillip, additional, Ritchie, Adam J, additional, Gilbert, Sarah C, additional, Xenopoulos, Alex, additional, Boumlic, Anissa, additional, and Douglas, Alexander D, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results